Pathological Positivity Rate in Prostate Cancer Patients with PI-RADS 4 and First Negative Biopsy

Recruiting Observational Study
Prostate Cancer
No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
Up to 75
Sex
Male
Study type
Observational
Participants needed
30 (estimated)
Sponsor
Anhui Provincial Hospital · Government
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The purpose of this prospective, single-center, single-arm trial was to evaluate the pathologic type of re-treatment based on a clear PI-RADS score of ≥4 with a first negative prostate biopsy, belonging to the high-risk group of the USTC diagnostic model, and PSMA PET/CT positive patients, and to evaluate the diagnostic efficacy of the USTC diagnostic model combined with PSMA PET/CT. At the same t…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * PI-RADS≥4 scores and the first prostate biopsy was negative * USTC clinical diagnosis model calculated risk probability value ≥0.6 * Reexamination of PSMA/PET-CT after the first puncture indicated positive prostatic lesions Exclusion Criteria: * Life expectancy is less than …
Contacts

Tao Tao, MD Ph.D

18856069828

taotao_urology@ustc.edu.cn

CONTACT